| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/30/2002 | WO2002007822A3 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 05/30/2002 | WO2002007677A3 Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder |
| 05/30/2002 | WO2001098280A3 5h-2,3-benzodiazepine antagonists of excitatory amino acid receptors |
| 05/30/2002 | WO2001096364A3 Peptides that stimulate cell survival and axon regeneration |
| 05/30/2002 | WO2001095928A3 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
| 05/30/2002 | WO2001092333A3 Use of adnf for enhancing learning and memory |
| 05/30/2002 | WO2001087913A3 Method for treating retinal degeneration with purinergic receptor agonists |
| 05/30/2002 | WO2001087330A3 Compositions and methods for achieving immune suppression |
| 05/30/2002 | WO2001085686A3 Multicyclic compounds and the use as inhibitors of parp, vegfr2 and mlk3 enzymes |
| 05/30/2002 | WO2001085149A3 Felbamate derived compounds |
| 05/30/2002 | WO2001082967A8 MEDICINAL COMPOSITIONS FOR SUPPRESSING β-AMYLOID PRODUCTION |
| 05/30/2002 | WO2001081413A3 Isolated human transporter proteins, nucleic acids and uses thereof |
| 05/30/2002 | WO2001079498A3 16051a and 16051b, novel human pdz family members and uses thereof |
| 05/30/2002 | WO2001072714A3 Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker |
| 05/30/2002 | WO2001068888A3 Production of chimeric capsid vectors |
| 05/30/2002 | WO2001066746A3 G-protein coupled receptor related polypeptides |
| 05/30/2002 | WO2001064877A3 Human schizophrenia gene |
| 05/30/2002 | WO2001043759A3 Use of 11cby popypeptides and polynuceotides |
| 05/30/2002 | WO2000078952A8 Human rna metabolism proteins (rmep) |
| 05/30/2002 | WO2000078296A3 Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders |
| 05/30/2002 | WO2000076489A3 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
| 05/30/2002 | WO2000052205A8 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE |
| 05/30/2002 | US20020065416 Anti-inflammatory agents |
| 05/30/2002 | US20020065415 For treating cerebral ischemia or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, neurodegenerative disorders |
| 05/30/2002 | US20020065393 Human hypoxanthine- (guanine) phosphoribosy1 transferase-2 |
| 05/30/2002 | US20020065319 For use in therapy of schizophrenia and/or tardive dyskinesia |
| 05/30/2002 | US20020065316 Citrullimycines, a process for their production and their use as pharmaceuticals |
| 05/30/2002 | US20020065315 For therapy and prophylaxis of asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, etc. |
| 05/30/2002 | US20020065302 Cyclic AMP-specific phosphodiesterase inhibitors |
| 05/30/2002 | US20020065301 Paroxetine compositions and processes for making the same |
| 05/30/2002 | US20020065299 Administering for therapy of mitochondria medited disease |
| 05/30/2002 | US20020065298 Mitochondria protecting agents for treating mitochondria associated diseases |
| 05/30/2002 | US20020065296 Administering heteroarylurea compound for therapy of cytokine mediated diseases and proteolytic enzyme mediated diseases |
| 05/30/2002 | US20020065294 Novel therapeutic use of 1,6-dimethyl-8b-hydroxymethyl-10a-methoxyergoline |
| 05/30/2002 | US20020065292 Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting ERAB or HADH2 activity |
| 05/30/2002 | US20020065290 Used as corticotropin-releasing factor (CRF) antagonists, in therapy and diagnosis of stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety |
| 05/30/2002 | US20020065289 Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| 05/30/2002 | US20020065285 Aromatic heterocyclic compounds as antiinflammatory agents |
| 05/30/2002 | US20020065284 Dipeptide derivatives |
| 05/30/2002 | US20020065278 Non-imidazole aryloxyalkylamines |
| 05/30/2002 | US20020065277 Administering to an obese patient or a patient at risk of becoming obese therapeutically effective amount of compound that attenuates binding of agouti-related protein to melanocortin receptors |
| 05/30/2002 | US20020065276 N-triazolymethyl-piperazine compounds with neurokinin-receptor antagonist activity |
| 05/30/2002 | US20020065274 Methods of using novel compounds as neuro-protective agents |
| 05/30/2002 | US20020065272 Olanzapine-N-oxide compositions and methods |
| 05/30/2002 | US20020065265 Antipsychotic sulfonamide-heterocycles, and methods of use thereof |
| 05/30/2002 | US20020065264 Heterocylic leaving group containing -o-Het, or -s-Het, wherein Heterocyclic rings selected from pyridine, pyrole, furan, pyrimidine or proline derivatives |
| 05/30/2002 | US20020065259 Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| 05/30/2002 | US20020065220 For use in diagnosis and therapy of disorders treating disorders related to these novel human immunoglobulin-like (Ig- like) proteins |
| 05/30/2002 | US20020064856 Novel proteases |
| 05/30/2002 | US20020064851 Peptide for use in development of human diagnostics and therapeutics; for use in deection and treatment of cancer, inflammation, immune disorders and development defects |
| 05/30/2002 | US20020064833 Nucleotide sequences for use in the treatment of drug abuse and drug dependence |
| 05/30/2002 | US20020064830 Nucleotide sequences for use as diagnostic tools |
| 05/30/2002 | US20020064826 Cytokine receptor-like polynucleotides, polypeptides, and antibodies |
| 05/30/2002 | US20020064823 Nucleotide sequences which code binding protein for use in human therapeutics and gene therapy |
| 05/30/2002 | US20020064821 Isolated human ion channel proteins, nucleic acid molecules encoding human ion channel proteins, and uses thereof |
| 05/30/2002 | US20020064811 Dna encoding the human synapsin iii gene and uses thereof |
| 05/30/2002 | US20020064569 Use of valeriana for the treatment of Restless Leg Syndrome and related disorders |
| 05/30/2002 | US20020064563 Core particles which are coated with a taste mask coating to provide coated particles which can be sprinkled onto food to ease administration to patients who have difficulty swallowing tablets or capsules |
| 05/30/2002 | US20020064536 Immobilizing a mammal by administering the toxin with a polysaccharide stabilizer, nonimmunogenic; use after surgery such as hip displasia or to recover from leg injuries in domestic animals |
| 05/30/2002 | US20020064527 Administering agents that hinder CD30/CD30L (CD30L=ligand of CD30) binding; animal model of arthritis for drug screening |
| 05/30/2002 | US20020064524 Formulation for topical non-invasive application in vivo |
| 05/30/2002 | CA2429699A1 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 05/30/2002 | CA2429630A1 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 05/30/2002 | CA2429605A1 Indol derivative and their use as inhibitors of p38 kinase |
| 05/30/2002 | CA2429579A1 Truncated cd200 |
| 05/30/2002 | CA2429570A1 Pyrimidine derivatives |
| 05/30/2002 | CA2429442A1 Aminothiazoles and their use as adenosine receptor antagonists |
| 05/30/2002 | CA2429328A1 Substituted cyclohexane derivates and the use thereof in medicaments for treating cardiovascular diseases |
| 05/30/2002 | CA2429313A1 Novel sulfonamide-substituted pyrazolopyridine derivatives |
| 05/30/2002 | CA2429310A1 Repinotan kit |
| 05/30/2002 | CA2429309A1 Novel carbamate-substituted pyrazolopyridine derivatives |
| 05/30/2002 | CA2428191A1 Acid derivatives useful as serine protease inhibitors |
| 05/30/2002 | CA2427931A1 Indole derivatives and medical applications thereof |
| 05/30/2002 | CA2427661A1 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| 05/30/2002 | CA2427444A1 3-arylindole derivatives and their use as cb2 receptor agonists |
| 05/30/2002 | CA2427330A1 Inhibitors of abc drug transporters at the blood-brain barrier |
| 05/30/2002 | CA2427184A1 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| 05/30/2002 | CA2426939A1 Cystoskeleton-associated proteins |
| 05/30/2002 | CA2363951A1 Modulating ramp activity |
| 05/30/2002 | CA2327208A1 Methods of increasing distribution of therapeutic agents |
| 05/29/2002 | EP1209229A1 Gene involved in schizophrenia |
| 05/29/2002 | EP1209157A1 Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds |
| 05/29/2002 | EP1209151A1 4-substituted piperidine derivatives |
| 05/29/2002 | EP1208842A2 Regulation of the immune system |
| 05/29/2002 | EP1208841A1 Neuropathy remedies |
| 05/29/2002 | EP1208838A2 Pure S(+)isomer fluoxetine |
| 05/29/2002 | EP1208235A1 Abc transport polynucleotides, polypeptides, and antibodies |
| 05/29/2002 | EP1208228A2 Differential gene expression in specific regions of the brain in neurodegenerative diseases |
| 05/29/2002 | EP1208225A2 Single nucleotide polymorphisms in mitochondrial genes that segregate with alzheimer's disease |
| 05/29/2002 | EP1208201A2 Compositions and methods for the treatment of immune related diseases |
| 05/29/2002 | EP1208198A2 Egfh2 genes and gene products |
| 05/29/2002 | EP1208112A1 Drug target isogenes: polymorphisms in the 5-hydroxytryptamine receptor 1a gene |
| 05/29/2002 | EP1208104A2 Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 05/29/2002 | EP1208103A2 Reverse-turn mimetics and methods relating thereto |
| 05/29/2002 | EP1208101A1 Vitronectin receptor antagonists useful for the treatment of strokes |
| 05/29/2002 | EP1208100A1 Selective antagonists of a2b adenosine receptors |
| 05/29/2002 | EP1208097A2 Substituted oxoazaheterocyclyl compounds |
| 05/29/2002 | EP1208085A2 Benzanilides as potassium channel openers |
| 05/29/2002 | EP1207897A2 Pharmaceutical compositions containing tripeptides |
| 05/29/2002 | EP1207882A1 Acyclic and cyclic amine derivatives |